Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros









Base de dados
Assunto principal
Intervalo de ano de publicação
1.
Intraperitoneal Carboplatin for Ovarian Cancer - A Phase 2/3 Trial.
Nagao, Shoji; Fujiwara, Keiichi; Yamamoto, Kouji; Tanabe, Hiroshi; Okamoto, Aikou; Takehara, Kazuhiro; Saito, Motoaki; Fujiwara, Hiroyuki; Tan, David S P; Yamaguchi, Satoshi; Adachi, Sosuke; Kikuchi, Akira; Hirasawa, Takeshi; Yokoi, Takeshi; Nagai, Tomonori; Sato, Toyomi; Kamiura, Shoji; Fujishita, Akira; Loong, Wong Wai; Chan, Karen; Syks, Peter; Olawaye, Alexsander; Ryu, Sang-Young; Shigeta, Hiroyuki; Kondo, Eiji; Yokoyama, Yoshihito; Matsumoto, Takashi; Hasegawa, Kosei; Enomoto, Takayuki.
NEJM Evid ; 2(5): EVIDoa2200225, 2023 May.
Artigo em Inglês | MEDLINE | ID: mdl-38320049

RESUMO

Intraperitoneal Carboplatin for Ovarian CancerThis trial compared intravenous weekly paclitaxel administered with intraperitoneal or intravenous carboplatin. There was a statistically significant increase in progression-free survival in patients with ovarian cancer treated with intraperitoneal versus intravenous carboplatin and paclitaxel, with no difference in overall survival between groups.


Assuntos
Neoplasias Ovarianas , Humanos , Feminino , Carboplatina , Neoplasias Ovarianas/tratamento farmacológico , Paclitaxel , Intervalo Livre de Progressão , Administração Intravenosa
ENVIAR RESULTADO:
Email
Exportar
Imprimir
RSS
XML
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA